Trial Profile

A Translational Phase I, Randomized, Parallel-group, Multi-arm Study to Evaluate Safety and Immunogenicity of an Influenza Vaccine Formulation Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Augment Tasmania influenza vaccine Sanofi (Primary) ; TIV 2X Darwin influenza vaccine Sanofi (Primary) ; Trivalent Tasmania influenza vaccine Sanofi (Primary) ; Trivalent-Darwin influenza vaccine Sanofi
Indications Influenza virus infections
Focus Adverse reactions
Sponsors Sanofi Pasteur

12 Mar 2025 Status changed from active, no longer recruiting to completed.
07 Feb 2025 Planned End Date changed from 31 Mar 2025 to 26 Feb 2025.
07 Feb 2025 Planned primary completion date changed from 31 Mar 2025 to 26 Feb 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com